Abstract：
OBJECTIVE: Carbonic anhydrase inhibitors (CAIs) are intraocular pressure-reducing medications used in ophthalmology. Human leukocyte antigen-B*59:01 (HLA-B*59:01) is strongly associated with CAI-induced severe cutaneous adverse reactions (SCARs). This study aimed to develop and validate a rapid and economical screening method for HLA-B*59:01 to prevent carbonic anhydrase inhibitor-induced SCARs.
METHODS: Duplex allele-specific polymerase chain reaction (PCR) with an internal control was performed for HLA-B*59:01 genotyping. The accuracy of duplex allele-specific PCR for HLA-B*59:01 genotyping was evaluated in 200 blood samples, using sequence-based typing (SBT) as the reference method.
RESULTS: In total, 50 HLA-B*59:01-positive and 150 HLA-B*59:01-negative results obtained using duplex allele-specific PCR were in complete agreement with the SBT results.
CONCLUSIONS: Duplex allele-specific PCR is a rapid, reliable, and economical assay for screening the HLA-B*59:01 allele.
METHODS: Duplex allele-specific polymerase chain reaction (PCR) with an internal control was performed for HLA-B*59:01 genotyping. The accuracy of duplex allele-specific PCR for HLA-B*59:01 genotyping was evaluated in 200 blood samples, using sequence-based typing (SBT) as the reference method.
RESULTS: In total, 50 HLA-B*59:01-positive and 150 HLA-B*59:01-negative results obtained using duplex allele-specific PCR were in complete agreement with the SBT results.
CONCLUSIONS: Duplex allele-specific PCR is a rapid, reliable, and economical assay for screening the HLA-B*59:01 allele.
摘要：
目的：碳酸酐酶抑制剂（CAIs）是眼科使用的降低眼内压的药物。人类白细胞抗原-B*59:01（HLA-B*59:01）与CAI诱导的严重皮肤不良反应（SCAR）密切相关。本研究旨在开发和验证一种快速，经济的HLA-B*59：01筛查方法，以预防碳酸酐酶抑制剂诱导的SCAR。
方法：用内部对照进行双重等位基因特异性聚合酶链反应（PCR）进行HLA-B*59:01基因分型。在200份血液样本中评估了双重等位基因特异性PCR对HLA-B*59:01基因分型的准确性，使用基于序列的分型(SBT)作为参考方法。
结果：总计，使用双链体等位基因特异性PCR获得的50个HLA-B*59:01阳性和150个HLA-B*59:01阴性结果与SBT结果完全一致。
结论：双重等位基因特异性PCR是一种快速，可靠,和筛选HLA-B*59:01等位基因的经济试验。
方法：用内部对照进行双重等位基因特异性聚合酶链反应（PCR）进行HLA-B*59:01基因分型。在200份血液样本中评估了双重等位基因特异性PCR对HLA-B*59:01基因分型的准确性，使用基于序列的分型(SBT)作为参考方法。
结果：总计，使用双链体等位基因特异性PCR获得的50个HLA-B*59:01阳性和150个HLA-B*59:01阴性结果与SBT结果完全一致。
结论：双重等位基因特异性PCR是一种快速，可靠,和筛选HLA-B*59:01等位基因的经济试验。
